EUCTR2019-003721-25-SE进行中（未招募）1 期
Randomized prospective phase II clinical trial investigating pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in an shortened tuberculosis treatment compared to standartd treatment for a group of patients with mild to moderate active tuberculosis.HIGH-SHORT RP - HIGH SHORT RP
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Patient> 18 years
- •2) Confirmed active lung TB by positive culture or positive PCR for the M.tuberculosis complex.
- •3) Planned to start on active TB treatment (first line) but not yet started treatment.
- •4) HIV negative
- •5) BMI> 17
- •6) Have given written consent.
- •7) Fertile women should use adequate non-hormonal contraceptives such as a condom and submit to a serum negative pregnancy test if the woman is not postmenopausal. Female patients are not considered fertile if they are post-menopausal, without menstruation for the last 12 months or surgically sterile (bilateral oophorectomy, hysterectomy, tubal ligation 12 months before study start).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1) The research person is not able to give informed consent or is considered so affected by his illness that he or she is unable to understand the study information.
- •2) Other concurrent infectious disease requiring active treatment.
- •3) Known hypersensitivity to rifamycin, isoniazid, pyrazinamide, etambutol hydrochloride and / or to any of the excipients listed in section Summary of Product Characteristics or previous serious adverse reaction to RIF, INH, PZA or EMB.
- •4) Contraindications according to the summary of product characteristics of RIF, INH, PZA or EMB:
- •Known hypersensitivity according to exclusion criterion 3 above and severe renal failure (creatinine clearance <30 ml / min) which coincides with exclusion criterion 13 below.
- •Previously drug-induced liver inflammation
- •Previous acute liver diseases regardless of cause
- •Acute liver disease regardless of cause
- •Severe liver disease
- •Porphyria
- •Previously serious adverse reactions when treated with any of the drugs such as drug-induced fever, chills or arthritis
- •Concomitant use of drugs whose therapeutic efficacy is very important for the patient whose plasma concentrations are markedly lowered by RIF, and where compensatory dose adjustments to maintain efficacy cannot be made, such as voriconazole, nifedipine, artemeter-lumefantrine and protease inhibitors (see section FASS Interactions)
- •Manifest Icterus
- •Acute arthritis
- •5) Treated for active TB in the last year before inclusion.
- •6) Resistance to any of the drugs (RIF, INH, PZA, EMB) included in standard tbc treatment according to molecular biological or phenotypic resistance assay.
- •7) Miliary tuberculosis
- •8) Pulmonary tuberculosis with any of the following:
- •(a) the presence of copious amounts of acid-fast rods (grade 3) in any of the clinical sputum tests
- •(b) pulmonary x-ray changes graded to advanced TB (according to the National Tuberculosis Association, 1961)
- •9) Extra-pulmonary tuberculosis without simultaneous pulmonary tuberculosis.
- •10) Pregnancy and breastfeeding.
- •11) Immunosuppression (known primary or secondary immunodeficiency including immunosuppressive treatment such as cytostatics, immunomodulatory therapy,> / = 15 mg prednisolone or equivalent cortisone dose)
- •12) Heart failure fulfilling NYHA Class III or IV
- •13) Renal failure with estimated GFR <50 mL / min (according to accredited laboratory method)
- •14) Not well-regulated diabetes mellitus with HbA1c> 62 mmol /mol for type I diabetes and HbA1c> 52 mmol /mol for type II diabetes.
- •15) Known liver disease including hepatitis and elevated liver transaminases (transaminases> x1.5 of the reference value).
- •16) Alcohol and / or drug dependence based on patient history.
- •17) A research person who the investigator after discussing with the study leader, forother reasons than the above, is deemed not suitable for inclusion.
- •18) Weight <35 kg or> 90 kg at inclusion
- •19) Patient participated in a clinical trial within 30 days prior to inclusion.
研究者
相似试验
进行中（未招募）
不适用
Randomized prospectic clinical trial Phase II in patients affected by prognostic class RPA V and VI glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two weeks) and esclusive temozolomide (TMZ)(200 mg/m2 for 5 days every 28) - AOBS-RT-TMZPatients with histological diagnosis od glioblastoma in RPA class V and VI and age =>65 yrs.MedDRA version: 9.1Level: SOCClassification code 10029104EUCTR2009-016813-11-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
进行中（未招募）
不适用
A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancerAdvanced breast cancerEUCTR2012-003743-30-SEKarolinska University Hospital
已完成
不适用
Prospective randomised phase II clinical trial of epirubicin, cisplatin, continuous infusional 5-fluorouracil (ECF) versus epirubicin, cisplatin and capecitabin (ECX) in patients with advanced gastric cancerCancerISRCTN72792659Ministry of Higher Education, Science and Technology (Slovenia)80
进行中（未招募）
不适用
A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIBChronic Phase Chronic myelogenous leukemia (CP CML)EUCTR2010-019568-35-FRCH VERSAILLES
进行中（未招募）
1 期
A randomized clinical study to investigate the efficiency of a novel anti-cancer medication against neuroblastoma in children, adolescent and young adults in whom the tumor relapsed or was refractory to standard careRelapsed or refractory high risk neuroblastomaEUCTR2011-004062-15-DEniversity Hospital of Regensburg114